?> RELIEF Study Challenges Restrictive Fluid: Oesophageal Doppler Removes Guesswork - DirectorsTalk

RELIEF Study Challenges Restrictive Fluid: Oesophageal Doppler Removes Guesswork

The Royal College of Anaesthesia held its flagship event, Anaesthesia 2018 at The British Museum on May 22nd and 23rd. Comprising two days of talks, breakout sessions and debates, it also featured the presentation of the RELIEF study, just published in the New England Journal of Medicine. “Restrictive versus liberal fluid therapy in major abdominal surgery (RELIEF)” was a 3000 patient pragmatic study across 46 hospitals in 7 countries. TopMedTalk, purveyor of the latest medical news, interviewed principal author Professor Paul Myles about the study and its implications.

Prof Myles pointed to the consistent, coherent recurring theme of increased Surgical Site Infection (SSI) and Acute Kidney Injury (AKI) in the fluid-restricted group compared with liberal fluids group. He said researchers “could not find any positive feature whatsoever in the restrictive/zero fluid balance group.” When asked about Enhanced Recovery after Surgery (ERAS) principles (which talk of restrictive fluid regimes) Prof Myles stated “I think ERAS and ERAS principles remain incredibly important, but that one item of giving a more restrictive i/v fluid approach, I think needs to be changed.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    Deltex Medical Group plc in a strong financial position

    Nigel Keen, Chairman of Deltex Medical, commented: “The successful £2,050,000 fund raising in February 2018 has put the Group in a stronger financial position – allowing us to improve our business structure. “We made a number

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group New CEO Andy Mears

    Deltex Medical Group Plc (LON:DEMG) New CEO Andy Mears talks to DirectorsTalk about his new position. Andy talks about his background, how he thinks Deltex is positioned, his plans for the next 12 months and the

    Deltex Medical Group Plc

    Deltex Medical Group plc New Chief Executive

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, announced today that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect. Mr. Phillips recently approached Deltex’s

    Deltex Medical Group Plc

    Another Successful Learning Event Sponsored by Deltex

    May 28th saw Deltex Medical Group supporting Current Initiatives, Research and the Role of Haemodynamic Monitoring at London’s Montague Hotel. Held under the auspices of the EBPOM organisation (Evidence Based PeriOperative Medicine), the congress saw keynote presentations from

    Deltex Medical Group Plc

    CEO Q&A with Ewan Phillips at Deltex Medical Group plc (LON:DEMG)

    Deltex Medical Group’s Ewan Phillips discusses their full year results, what’s been happening operationally, their strategy for the next 12 months and what investors should look forward to in the near future in this exclusive interview with DirectorsTalk

    Deltex Medical Group Plc

    Deltex Medical Group PLC Investor Event

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), today announced that it will be hosting an investor event on 22 May 2018 following the publication of its full year results for

    Deltex Medical Group Plc

    Deltex Sponsoring Evidence-Based Clinical Event

    Deltex Medical will be supporting a forthcoming congress in London on May 28th. Current Initiatives, Research and the Role of Hemodynamic Monitoring is free to attend for clinicians and healthcare providers who are interested in the principles and

    Deltex Medical Group Plc

    Critical caring

    It takes a plethora of products and people to provide patients premium protection. Changing payment models, the digitization of healthcare and the need to deliver higher quality care at a lower cost are driving significant change

    Deltex Medical Group Plc

    FEDORA Study “Take-Homes” for clinicians

    Clinician-led disseminator of medical news, TopMedTalk has reviewed the landmark FEDORA study into Goal-Directed Haemodynamic Therapy (GDHT). Reinforcing the conclusions from meta-analysis of 70 other studies, FEDORA supports the use of Oesophageal Doppler to derive clinical parameters that